The AHCYL2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 cell line, engineered to ablate expression of the scaffold protein AHCYL2 (also known as IRBIT2). This genetically disrupted pool serves as a versatile loss-of-function model for investigating AHCYL2-dependent cellular processes. The polyclonal format preserves population diversity while eliminating functional AHCYL2 protein, enabling robust functional genomics studies without the need for clonal selection. Researchers can employ these cells to interrogate the roles of AHCYL2 in intracellular calcium dynamics, ion transport regulation, and signaling networks critical to both normal and malignant epithelial physiology.
The parental A-549 cell line was originally established from the lung adenocarcinoma of a 58-year-old Caucasian male, and it is widely utilized as a model of human alveolar type II epithelium. A-549 cells display a hypotriploid karyotype and retain features characteristic of pulmonary adenocarcinoma, including lamellar body formation and surfactant production. Their epithelial origin and tumorigenic properties make them a relevant platform for lung cancer research and for studies of respiratory epithelial function, drug metabolism, and host-pathogen interactions. Within this background, AHCYL2 knockout enables researchers to dissect the gene??s contributions to cancer cell biology and ion transport homeostasis.
AHCYL2 encodes a multifunctional scaffold protein that regulates intracellular calcium signaling and ion transport by binding IP3 receptors and modulating multiple effectors. Its phosphorylation state, controlled by kinases such as CaMKII, PKA, and PKC, determines its association with ion transporters including NHE3, CFTR, NBCe1, and SLC26A6. In its dephosphorylated form, AHCYL2 activates these transporters, whereas phosphorylation induces dissociation, enabling dynamic control of ion flux. The protein also interacts with PP1, integrating upstream calcium and cAMP signals. Through these interactions, AHCYL2 influences cellular pH, volume, and transepithelial ion movement, serving as a critical node in calcium, inositol phosphate, and cAMP signaling pathways.
In the A-549 lung adenocarcinoma model, AHCYL2 disruption provides a tool to study calcium signaling and ion transport in cancer. AHCYL2 is a putative tumor modulator with altered expression in colorectal, gastric, and breast cancers; its knockout may reveal roles in lung tumor biology. A-549 cells express functional CFTR and other transporters, allowing dissection of AHCYL2??s regulation of fluid balance and pH homeostasis in alveolar epithelium. This model can illuminate mechanisms in respiratory diseases, hypertension, and neurodevelopmental disorders. Comparative studies can assess changes in proliferation, migration, and drug responses.
These AHCYL2 polyclonal knockout cells are suited for calcium signaling studies, ion transport regulation, and cancer cell biology. Applications include calcium imaging, co-immunoprecipitation, western blotting, RT-qPCR, immunofluorescence, intracellular pH measurement, and cell proliferation assays. Sanger sequencing can confirm gene disruption. The polyclonal nature minimizes clone-specific artifacts, supporting robust functional screens. For further details, contact Ascent Research.
